Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

M N Silverstein

Showing results (41-50 of 67) with videos related to

Pageof 7
Sort By:
Cancer Treatment Reports|January 1, 1977
Pilot study of two adriamycin-based regimens in patients with advanced malignant lymphomasM J O'Connell, M N Silverstein, J M Kiely, et al.
Mayo Clinic Proceedings|June 1, 1970
Lymphosarcoma with Bence Jones proteinuria (type K) and IgG serum M-component (type L): a bitypic gammopathyJ E Maldonado, R C Williams, M N Silverstein, et al.
Blood|March 25, 2000
Splenectomy in myelofibrosis with myeloid metaplasia: a single-institution experience with 223 patientsA Tefferi, R A Mesa, D M Nagorney, et al.
American Journal of Hematology|May 20, 1999
Population-based incidence and survival figures in essential thrombocythemia and agnogenic myeloid metaplasia: an Olmsted County Study, 1976-1995R A Mesa, M N Silverstein, S J Jacobsen, et al.
Journal of the National Cancer Institute|September 15, 1993
Suramin toxicity and efficacy in agnogenic myeloid metaplasiaA Tefferi, M N Silverstein, E A Plumhoff, et al.
Archives of Internal Medicine|June 12, 1995
Outcome analysis of 34 pregnancies in women with essential thrombocythemiaA H Beressi, A Tefferi, M N Silverstein, et al.
Seminars in Thrombosis and Hemostasis|January 1, 1997
Anagrelide as a new platelet-lowering agent in essential thrombocythemia: mechanism of actin, efficacy, toxicity, current indicationsA Tefferi, M N Silverstein, R M Petitt, et al.
Cancer Genetics and Cytogenetics|November 1, 1985
Deletions of chromosome 13 in malignant hematologic disordersD D Johnson, G W Dewald, R V Pierre, et al.
Cancer Treatment Reports|January 1, 1980
Randomized clinical trial comparing two dose regimens of ICRF-159 in refractory malignant lymphomasM J O'Connell, C B Begg, M N Silverstein, et al.
Archives of Internal Medicine|January 1, 1972
Idiopathic acquired hemolytic anemia. Survival in 117 casesM N Silverstein, M R Gomes, L R Elveback, et al.
Pageof 7

Showing results (41-50 of 67) with videos related to

Sort By:
Pageof 7
Cancer Treatment Reports|January 1, 1977
Pilot study of two adriamycin-based regimens in patients with advanced malignant lymphomasM J O'Connell, M N Silverstein, J M Kiely, et al.
Mayo Clinic Proceedings|June 1, 1970
Lymphosarcoma with Bence Jones proteinuria (type K) and IgG serum M-component (type L): a bitypic gammopathyJ E Maldonado, R C Williams, M N Silverstein, et al.
Blood|March 25, 2000
Splenectomy in myelofibrosis with myeloid metaplasia: a single-institution experience with 223 patientsA Tefferi, R A Mesa, D M Nagorney, et al.
American Journal of Hematology|May 20, 1999
Population-based incidence and survival figures in essential thrombocythemia and agnogenic myeloid metaplasia: an Olmsted County Study, 1976-1995R A Mesa, M N Silverstein, S J Jacobsen, et al.
Journal of the National Cancer Institute|September 15, 1993
Suramin toxicity and efficacy in agnogenic myeloid metaplasiaA Tefferi, M N Silverstein, E A Plumhoff, et al.
Archives of Internal Medicine|June 12, 1995
Outcome analysis of 34 pregnancies in women with essential thrombocythemiaA H Beressi, A Tefferi, M N Silverstein, et al.
Seminars in Thrombosis and Hemostasis|January 1, 1997
Anagrelide as a new platelet-lowering agent in essential thrombocythemia: mechanism of actin, efficacy, toxicity, current indicationsA Tefferi, M N Silverstein, R M Petitt, et al.
Cancer Genetics and Cytogenetics|November 1, 1985
Deletions of chromosome 13 in malignant hematologic disordersD D Johnson, G W Dewald, R V Pierre, et al.
Cancer Treatment Reports|January 1, 1980
Randomized clinical trial comparing two dose regimens of ICRF-159 in refractory malignant lymphomasM J O'Connell, C B Begg, M N Silverstein, et al.
Archives of Internal Medicine|January 1, 1972
Idiopathic acquired hemolytic anemia. Survival in 117 casesM N Silverstein, M R Gomes, L R Elveback, et al.
Pageof 7